Dr. Kalinichev is a Director, in vivo Neurology at Ipsen Innovation in France, where he leads the in vivo pharmacology research in the area of neurological disorders and neurotoxins. Dr. Kalinichev received his PhD in Behavioral Neuroscience from Rutgers University (USA). Following a post-doc at the Emory University School of Medicine in Atlanta, he joined the Psychiatry Center of Excellence at GlaxoSmithKline in Harlow, UK to lead in vivo support of several drug discovery programs. In 2009 Dr. Kalinichev joined Addex Therapeutics in Geneva to lead the in vivo pharmacology research, while also playing part in setting therapeutic strategy, business development and external research collaborations and partnerships. From 2014-2015 Dr. Kalinichev was working at Lundbeck pharmaceuticals in Copenhagen, Denmark, leading the in vivo pharmacology research in the area of cognitive impairment associated with psychiatric and neurodegenerative disorders and pain. Dr. Kalinichev received numerous honors and awards, including The GlaxoSmithKline Exceptional Science Award and The Vernalis Prize of the British Association for Psychopharmacology. He has published over 40 articles and book chapters in the area of drug discovery in psychiatry and neurology.